Method for diagnosing and/or predicting of a septic syndrome

• US 7,622,249 B2
• Filed: 06/02/2004
• Issued: 11/24/2009
• Est. Priority Date: 06/03/2003
• Status: Active Grant

• Current Assignee: Biomerieux B.V. (Compagnie Merieux Alliance SAS)
• Original Assignee: Biomerieux B.V. (Compagnie Merieux Alliance SAS)
• Inventors: Pachot, Alexandre
• Primary Examiner(s): Johannsen; Diana B
• Application Number:
  US10/559,292
• Publication Number:
  US 20060127912A1
• Time in Patent Office: 2,001 Days
• Field of Search: None
• US Class Current: 435/6.16
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates to a method for diagnosing and/or predicting a septic syndrome, wherein:

• • a. a biological sample from the patient is made available and biological material is extracted from the biological sample
  • b. at least four specific reagents which are selected from the following specific reagents are made available: reagent which is specific for the target gene IL-10, reagent which is specific for the target gene TGFβ, reagent which is specific for the target gene HMG1, reagent which is specific for the target gene T-bet, reagent which is specific for the target gene IL-1β, reagent which is specific for the target gene TNFα and reagent which is specific for the target gene GATA-3
  • c. the expression of at least four target genes selected from: IL-10, TGFβ, HMG1, T-bet, IL-1β, TNFα and GATA-3 is determined.

The present invention also relates to a kit for diagnosing and/or predicting a septic syndrome.

Claims

1. A method for diagnosing and/or predicting a septic syndrome, the method comprising:

a. obtaining a blood sample from a patient;

b. extracting biological material from the blood sample;

c. contacting the biological material with;

a reagent for demonstrating expression of IL-10 gene,

a reagent for demonstrating expression of TGFβ

gene,

a reagent for demonstrating expression of HMG1 gene,

a reagent for demonstrating expression of IL-1β

gene; and

a reagent for demonstrating expression of T-bet gene;

d. determining the expression levels of the IL-10 gene, TGFβ

gene, the HMG1 gene, the IL-1β

gene and the T-bet gene in said blood sample; and

e. comparing the expression levels of the IL-10 gene, the TGFβ

gene, the HMG1 gene, the IL-1β

gene and T-bet gene in said blood sample to known control mean expression values of each of the genes in order to diagnose and/or predict a septic syndrome based on a variation in the expression of each gene in the blood sample when compared to the corresponding known control mean expression value.

2. The method of claim 1, wherein the biological material is a nucleic acid.

3. The method of claim 1, wherein:

the reagent for demonstrating expression of the IL-10 gene comprises at least one amplification primer specific for the IL-10 gene;

the reagent for demonstrating expression of the TGFβ

gene comprises at least one amplification primer specific for the TGFβ

gene;

the reagent for demonstrating expression of the HMG1 gene comprises at least one amplification primer specific for the HMG1 gene;

the reagent for demonstrating expression of the IL-1β

gene comprises at least one amplification primer specific for the IL-1β

gene; and

the reagent for demonstrating expression of the T-bet gene comprises at least one amplification primer specific for the T-bet gene.

4. The method of claim 1, wherein:

the reagent for demonstrating expression of the IL-10 gene comprises at least one hybridization probe specific for the IL-10 gene;

the reagent for demonstrating expression of the TGFβ

gene comprises at least one hybridization probe specific for the TGFβ

gene;

the reagent for demonstrating expression of the HMG1 gene comprises at least one hybridization probe specific for the HMG1 gene;

the reagent for demonstrating expression of the IL-1β

gene comprises at least one hybridization probe specific for the IL-1β

gene; and

the reagent for demonstrating expression of the T-bet gene comprises at least one hybridization probe specific for the T-bet gene.